TMG (trimethylglycine)

TMG (Trimethylglycine): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Trimethylglycine is an amino acid derivative with the formula (CH₃)₃N⁺CH₂CO⁻₂. A colorless, water-soluble solid occurring in plants, trimethylglycine is a zwitterion: the molecule contains both a quaternary ammonium group and a carboxylate group. Betaine (trimethylglycine) is a natural product; it is a glycine derivatized by three extra methyl groups.

The compound is known by several synonyms. TMG is also known as betaine, glycine betaine, lycine, and oxyneurine. It is known as a "betaine" molecule ("betaine" being a category of molecules), but because it was the first dietary betaine discovered (from beetroot) and is the most popular molecule referred to as a betaine, the terms "trimethylglycine" and "betaine" are used interchangeably. A betaine is any neutral chemical compound with a positively charged cationic functional group that bears no hydrogen atom, and with a negatively charged functional group such as a carboxylate group; they are zwitterions but cannot isomerize because there is no labile hydrogen atom attached to the nitrogen atom.

Betaine (C₅H₁₁NO₂), also known as glycine betaine, and chemically named trimethylglycine, is a derivative of glycine which belongs to the quaternary amine-type water-soluble alkaloid class. Betaine is a heat-stable compound; the critical decomposition temperature of pure anhydrous betaine is up to 245°C.

Natural Sources and Occurrence

Betaine is a stable and harmless natural constituent that exists in plants, animals, and microorganisms. The most common dietary sources of betaine are beets, spinach, and whole grains. Whole grains — such as quinoa, wheat and oat brans, brown rice, barley, etc. — are generally considered rich sources of betaine.

USDA food-analysis data document the relative concentrations in specific foods. Of the foods analyzed, wheat bran and wheat germ have the highest concentration of betaine (>1 g/100 g). Baked products (33–226 mg/100 g), spinach, beets, crustaceans, and finfish are also good sources of betaine. Meats, poultry, fruits, nuts, and wine are generally not good sources of betaine (<6 mg/100 g). More precisely, spinach ranks among the most betaine-rich vegetables, containing approximately 577 to 645 mg per 100 grams.

TMG is synthesized by the body and can be found in foods like broccoli, spinach, and grains; however, cooking often diminishes its content. It is worth mentioning that betaine is also the main water-soluble component of traditional Chinese medicine Lycium barbarum.

Endogenous Biosynthesis

Betaine can be synthesized endogenously through choline metabolism, where choline dehydrogenase oxidizes choline to betaine aldehyde, which is then converted to betaine by betaine aldehyde dehydrogenase in the presence of nicotinamide adenine dinucleotide (NAD⁺). For human beings, betaine is an important nutrient, which is synthesized through the choline metabolic pathway and mainly exists in human liver and kidney. Choline (tetramethylglycine) has four methyl groups attached to it. When choline donates one of these groups to another molecule, it becomes betaine (trimethylglycine). If betaine donates one of its methyl groups, then it becomes dimethylglycine.

Common Supplement Forms and Preparations

Trimethylglycine is available as a supplement in powder, tablet, or capsule form. Many people prefer trimethylglycine powder as it mixes easily with water, juice, or smoothies, and it has a mild, slightly sweet taste.

Betaine is marketed under the brand name Cystadane. Trimethylglycine is also used as the hydrochloride salt (marketed as betaine hydrochloride or betaine HCl). Betaine hydrochloride was sold over-the-counter (OTC) as a purported gastric aid in the United States. Betaine is most widely available as betaine hydrochloride (betaine-HCl), which is used primarily as a source of hydrochloric acid for people with hypochlorhydria (low stomach acid). The forms used specifically to provide betaine are betaine citrate and betaine aspartate, which have also been used to improve liver function.

Either ingested as a dietary supplement or from food, betaine has similar bioavailability, being broken down to dimethylglycine and lastly to sarcosine in the mitochondria of kidney and liver cells.

Regarding regulatory status, in the United States, betaine is generally recognized as a safe (GRAS) ingredient, while in Europe it has approval for use in food from the European Commission (EC), which allows the safe use of betaine in food in an amount of at least 500 mg per food serving. TMG supplements, commonly referred to as betaine anhydrous, have not been approved by the FDA for medical use as a general dietary supplement; however, the US Food and Drug Administration (FDA) approved betaine trimethylglycine (also known by the brand name Cystadane) for the treatment of homocystinuria, a disease caused by abnormally high homocysteine levels at birth.

2. Historical and Traditional Use

Discovery and Early History

The original betaine, N,N,N-trimethylglycine, was named after its discovery in sugar beet (Beta vulgaris subsp. vulgaris) in the nineteenth century. Betaine was first discovered in beet juice in the 19th century. Since then, it has been increasingly reported that betaine is found in daily foods, such as spinach, wheat germ, and shrimp.

Trimethylglycine is a neutral zwitterionic compound that is naturally found in various foods, including sugar beets, wheat bran, and spinach. It is produced primarily as a natural byproduct extracted from molasses during sugar beet refinement. Commercial extraction from beet molasses became the basis for industrial production, which remains the primary commercial source today.

Traditional Use in Chinese Medicine

Betaine is the main water-soluble component of the traditional Chinese medicine herb Lycium barbarum (wolfberry or goji berry), which has been used in Chinese traditional medicine for centuries to support the liver, kidneys, and vision. The use of betaine within this context represents an indirect form of traditional TMG consumption, though specific historical attributions to betaine as an isolated compound did not exist prior to its nineteenth-century chemical characterization.

Early Pharmaceutical and Food Industry Use

Trimethylglycine is a cheap, natural, and highly biocompatible compound that has been used in the fields of food and life sciences. For many years, glycine betaine has been widely studied as an osmolyte in plants and bacteria. In animal cells, it is an osmolyte mainly in the kidneys, but in humans many studies have shown its role as a methyl donor in homocysteine metabolism in the liver. It is also a protein stabilizer and became known as an osmoprotector. In many organisms it is synthesized from choline and can also be obtained from some foods. Over the last twenty years, glycine betaine has gone from being considered simply as an osmolyte to being known as a cytoprotector involved in cell metabolism and as a chemical chaperone.

Betaine hydrochloride was sold over-the-counter as a purported gastric aid in the United States. US Code of Federal Regulations, Title 21, Section 310.540, which became effective in November 1993, banned the marketing of betaine hydrochloride as a digestive aid due to insufficient evidence to classify it as "generally recognized as safe and effective" for that specified use.

3. Key Constituents, Active Compounds, and Mechanisms of Action

Methyl Donation and the Methylation Cycle

Betaine (trimethylglycine) functions very closely with choline, folic acid, vitamin B12, and a form of the amino acid methionine known as S-adenosylmethionine (SAMe). All of these compounds function as "methyl donors" — they carry and donate methyl molecules to facilitate necessary chemical processes. One of betaine's major mechanisms is its role as a methyl donor.

Betaine acts as a methyl donor in the methionine cycle by donating a methyl group to homocysteine via betaine-homocysteine methyltransferase, leading to the formation of methionine and supporting the synthesis of S-adenosylmethionine (SAMe), a central methyl donor in cellular metabolism. The increased availability of SAMe, in turn, stimulates the synthesis of key biological compounds, such as creatine and carnitine.

The donation of methyl groups by betaine is very important to proper liver function, cellular replication, and detoxification reactions. Betaine also plays a role in the manufacture of carnitine and serves to protect the kidneys from damage.

Osmoprotection

Betaine plays several key physiological roles in mammals. First, it acts as an organic osmolyte, protecting cells from osmotic stress such as dehydration and adverse temperatures. It preserves cellular hydration while maintaining integrity of macromolecular functions and regulates fluid balance and trans-epithelial water movement, thereby assisting in cell volume regulation.

In contrast to other osmolytes and inorganic salts such as urea and Na⁺, betaine reduces the ability of water molecules to solvate proteins, thus stabilizing native protein structures. In addition, betaine can also increase the cytoplasmic volume and free water content of cells to prevent shrinkage in hyperosmotic conditions and to inhibit various hyperosmotic-induced apoptosis-related proteins.

The principal role of betaine in the kidney is osmoprotection in cells of the medulla, and it enters these cells via the betaine/γ-aminobutyric acid (GABA) transporter protein (BGT1), which is upregulated by hyperosmotic stress. Betaine also protects proteins from urea-induced denaturation by preventing the formation of folding intermediates that promote the loss of enzymatic structure and function. Moreover, as an osmolyte, betaine has been demonstrated to enhance water structure and promote tighter protein folding, which may further contribute to its stabilizing effects on protein conformation.

Anti-inflammatory Mechanisms

Betaine is known to function physiologically as an important osmoprotectant and methyl group donor. Accumulating evidence has shown that betaine has anti-inflammatory functions in numerous diseases. Mechanistically, betaine ameliorates sulfur amino acid metabolism against oxidative stress, inhibits nuclear factor-κB (NF-κB) activity and NLRP3 inflammasome activation, regulates energy metabolism, and mitigates endoplasmic reticulum stress and apoptosis.

The ability of betaine to scavenge reactive oxygen species (ROS) has not been determined by classical chemical assays such as the FRAP test. On the other hand, betaine's antioxidant activity has been determined in animal and plant models, suggesting that the interaction of betaine with the organism could be essential for its redox activity.

4. Scientific Evidence by Area of Use

4.1 Homocystinuria (FDA-Approved Medical Use)

The US Food and Drug Administration (FDA) approved betaine trimethylglycine (brand name Cystadane) for the treatment of homocystinuria. Specifically, the compound is indicated for the adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylene-tetrahydrofolate reductase (MTHFR), or cobalamin cofactor metabolism.

In certain rare genetic conditions such as homocystinuria, the body cannot dispose of homocysteine, which results in its accumulation at extremely high levels. This, in turn, leads to accelerated cardiovascular disease and other problems. Betaine serves as a methyl donor for the remethylation of homocysteine to methionine catalyzed by betaine-homocysteine methyltransferase in the liver. Untreated homocystinuria has a high rate of complications in the vasculature, connective tissue, and central nervous system. Treatments that lower serum homocysteine, such as a severely methionine-restricted diet and betaine, lower the associated clinical problems if executed well.

Evidence strength: Robust, supported by FDA approval. This represents the best-characterized and most clinically established application of TMG.

4.2 Cardiovascular Health and Homocysteine Reduction

Betaine (trimethylglycine) lowers plasma homocysteine, a possible risk factor for cardiovascular disease. However, studies in renal patients and in obese individuals on a weight-loss diet suggest that betaine supplementation raises blood cholesterol; data in healthy individuals were lacking. Such an effect on cholesterol would counteract any favorable effect on homocysteine.

A 2013 meta-analysis published in PMC examined the homocysteine-lowering effect specifically. The meta-analysis showed that supplementation of betaine at 4 to 6 g/d significantly lowers plasma homocysteine concentration in healthy adults by 1.23 μmol/L or 11.8% of baseline values. A reduction in plasma homocysteine of 5 μmol/L is estimated to reduce the risk of cardiovascular disease by 20% to 30% and stroke by 40% to 60%. Based on this meta-analysis, a person who consumes 4 to 6 g/d of betaine would have a 1.23-μmol/L lower plasma homocysteine concentration with an estimated concurrent reduction in cardiovascular disease risk of approximately 5% to 8% and a reduction in stroke risk of approximately 10% to 15%.

One important study examined vascular function directly. A methionine load with placebo increased homocysteine concentrations significantly; a methionine load together with betaine reduced the homocysteine increase. However, methionine loading with placebo did not affect flow-mediated dilation (FMD), and neither did methionine loading with folic acid, betaine, or serine. The authors concluded that experimentally induced acute changes in homocysteine concentrations did not affect FMD in healthy volunteers, implying that potential adverse effects of high homocysteine on the cardiovascular system are not mediated through vascular function.

Regarding dietary intake, a person who consumes a diet rich in betaine (~2 g/d) would have a 1.3 μmol/L (12%) lower plasma homocysteine concentration than a person consuming a diet poor in betaine (0.5 g/d). The concurrent reduction in cardiovascular disease risk would be approximately 5–8%. However, it is important to note that betaine supplementation might also increase serum cholesterol, which could diminish the health benefits. Whether homocysteine lowering results in a lower risk of cardiovascular disease is still under debate.

Evidence strength: Moderate for homocysteine reduction. The clinical implication for hard cardiovascular outcomes (heart attacks, strokes) remains uncertain because increases in LDL cholesterol at supplemental doses may offset any benefit from homocysteine reduction. More large-scale outcome trials are needed.

4.3 Liver Disease

Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic fatty liver (NAFL) is a common liver disease associated with insulin resistance. Betaine has been tested as a treatment for NAFL in animal models and in small clinical trials, with mixed results.

The key negative pivotal trial was published in Hepatology in 2009. Based on animal studies and pilot studies in humans, betaine — a methyl donor for the remethylation of homocysteine — was evaluated for safety and efficacy in patients with NASH. A randomized placebo-controlled study of 55 patients with biopsy-proven NASH received either oral betaine (20 g daily) or placebo for 12 months. Of the 35 patients who completed the study, patients randomized to betaine had a decrease in steatosis grade; however, no intra- or intergroup differences or changes in nonalcoholic fatty liver disease activity score or fibrosis stage were noted. Elevations of insulin, glucose, and proinflammatory cytokines and the reduced antioxidant status noted in NASH patients did not improve with betaine therapy. Compared to placebo, betaine did not improve hepatic steatosis but may protect against worsening steatosis.

More recent evidence shows promise. A hospital-based interventional investigation involving 244 NAFLD patients evaluated TMG safety and efficacy. This study involved 244 NAFLD patients; trimethylglycine, administered orally, consisted of 2 sachets three times daily for 1 month, followed by 1 sachet three times daily for the subsequent 2 months, each sachet containing 3 g of betaine. The findings suggest a crucial role for betaine in the treatment of NAFLD; however, further validation of its effectiveness is imperative through extensive, multicenter randomized studies.

Betaine plays important roles in regulating the genes associated with NAFLD through anti-inflammatory effects, increased free fatty oxidation, anti-lipogenic effects, and improved insulin resistance and mitochondrial function; however, the mechanism of betaine remains elusive.

Evidence strength: Preliminary and mixed. Animal model and in-vitro data are supportive, but the primary large human randomized controlled trial (Abdelmalek et al., 2009) did not find significant histological improvements. Smaller and more recent trials are suggestive of benefit in steatosis, but multicenter RCT data are lacking. This area requires further investigation.

Alcoholic Liver Disease

Oral betaine treatment has been evaluated in the treatment of alcoholic liver disease. For people with alcohol-induced fatty liver, the recommended amount for betaine citrate or betaine aspartate supplementation is 1,000 to 2,000 mg three times daily. Lower amounts are often used as nutritional support for general liver health, although use of betaine in this manner has not undergone rigorous clinical research.

Evidence strength: Preliminary. The evidence base consists largely of small trials and animal models, and strong clinical trial data specific to alcoholic liver disease in humans remain limited.

4.4 Athletic and Exercise Performance

Betaine (trimethylglycine) is an active metabolite of choline in the body and a component of beetroot. It serves a vital role in methylation in the body alongside folate, and is an osmoregulator like creatine. Betaine is also a possible ergogenic aid.

Evidence from individual studies is mixed. Using a double-blind crossover design, 10 handball players underwent high-intensity resistance exercise before and after 14 days of either placebo (maltodextrin) or betaine (2.5 g/d) supplementation, with a 30-day washout period separating each treatment. One earlier study referenced in the literature showed that ingestion of a betaine supplement for 14 days significantly improved bench press throw and vertical jump power, isometric bench press force, and isometric squat force in recreationally trained men. However, other investigators examining performance benefits from sub-chronic (2 weeks) betaine supplementation in resistance exercise reported equivocal evidence, with some reporting improvements in strength and power and others reporting no improvements in these performance parameters.

In response to the standard supplemental protocol (1.25 g of TMG, usually in 250 mL of carbohydrate solution, taken twice daily for two weeks), betaine has failed to increase power output in the bench or leg press exercises in resistance-trained men exercising in the fasted state, with no changes in eccentric or concentric power in weight training, and no changes to peak power on leg or chest exercises in college-aged men at one or two weeks. One study conducted in sedentary men given 2 g TMG for 10 days either in isolation or alongside 20 g of creatine failed to note any power enhancement either inherently with betaine or an enhancement of the creatine-induced increase in power output.

A 6-week intervention in collegiate athletes tested higher doses. Sixteen male collegiate athletes received 5 g/day of betaine or carboxymethyl cellulose (placebo) for 6 weeks. After supplementation, there were no significant differences between betaine and placebo groups on any variables. Compared to pre-supplementation, however, the performance of the overhead medicine-ball throw, and 1-RM of overhead press and half squat in the betaine group significantly improved.

A 2025 review of the literature in this area concluded: Although large-scale, multicenter studies remain limited, available evidence suggests potential ergogenic benefits such as improved lower-body strength and jump performance. Betaine supplementation is gaining popularity as a strategy to enhance physical performance, particularly in strength and endurance training. Supplementation may also influence hormonal balance by increasing the testosterone-to-cortisol ratio, promoting an anabolic state. Findings regarding betaine's impact on body composition remain mixed — some studies report no significant changes in lean mass or fat mass, while others suggest a reduction in fat mass without changes in overall body weight.

Evidence strength: Mixed and preliminary. Results are inconsistent across studies. The variation may relate to training status of subjects, exercise protocols, and dose employed. A 2017 review of seven studies found that only two demonstrated improvements in muscle strength and power. The field requires larger, well-standardized trials.

4.5 Inflammation and Chronic Disease

Accumulating evidence has shown that betaine has anti-inflammatory functions in numerous diseases. Mechanistically, betaine ameliorates sulfur amino acid metabolism against oxidative stress, inhibits NF-κB activity and NLRP3 inflammasome activation, regulates energy metabolism, and mitigates endoplasmic reticulum stress and apoptosis. Consequently, betaine has beneficial actions in several human diseases, such as obesity, diabetes, cancer, and Alzheimer's disease.

Evidence strength: Largely preclinical. The majority of this evidence derives from animal models and in-vitro studies. Human clinical evidence for betaine's anti-inflammatory effects as a standalone intervention remains limited.

4.6 Diabetes and Insulin Resistance

In animal models of NAFLD, betaine treatment improved insulin and glucose levels, whereas betaine administration to humans with nonalcoholic steatohepatitis decreased indexes of steatosis. Limited epidemiological evidence in humans exists, including one large observational study associated with choline and betaine intake.

Evidence strength: Preliminary. Most evidence derives from animal studies or observational analyses. Controlled human intervention trials specifically targeting insulin resistance with betaine are limited and insufficient to support definitive conclusions.

4.7 Kidney Protection

It is well established that the primary role of betaine in the kidney is osmoprotection. The always high but changing extracellular osmolarity in the kidney medulla plays an essential role in urine concentration. To balance the high osmolarity and preserve cell volume without interfering with cell function, one well-characterized mechanism is to accumulate compatible osmolytes. Betaine, sorbitol, myo-inositol, taurine, and glycerolphosphorylcholine are the predominant osmolytes in the mammalian kidney.

Increased renal excretion of betaine contributes to decreased concentration of the protective osmolyte in tissues of hypertensive rats. These findings pave the way for studies evaluating a causal relation between depleted betaine and hypertensive organ damage, including kidney injury.

Evidence strength: The physiological role of betaine as a renal osmolyte is well established in basic science. Human intervention studies specifically evaluating betaine supplementation for kidney protection are not yet available.

4.8 Autism Spectrum Disorder

Dimethylglycine (DMG) and trimethylglycine (TMG) are both derivatives of glycine and have been posited to reduce lactic acid, enhance oxygen use, and reduce seizure activity during times of stress. The use of DMG and TMG is based on the theory that metabolic derangements contribute to the development of autism. There has been very little research on the use of DMG and TMG, with only 2 studies reporting essentially no benefits of the use of DMG in patients with autism.

Evidence strength: Very weak. The limited controlled trials available have not demonstrated benefit, and use in autism is not supported by current clinical evidence.

5. Body Systems and Health Areas of Association

• Cardiovascular system: Homocysteine metabolism, methylation, and effects on blood lipids (LDL, triglycerides).
• Hepatic system: Methyl donation, phosphatidylcholine synthesis, osmoprotection in liver cells, and effects on hepatic steatosis and inflammation.
• Renal system: Primary osmolyte in the kidney medulla; accumulates via BGT1 transporter to maintain cell integrity under hyperosmotic conditions.
• Musculoskeletal system: Proposed role as osmolyte in skeletal muscle, support for creatine and carnitine biosynthesis, and potential ergogenic effects on exercise performance.
• Metabolic system: Involvement in methionine cycle; potential influence on insulin sensitivity and glucose metabolism.
• Central nervous system: SAMe production (which affects neurotransmitter synthesis), and its role as a component of Lycium barbarum used in traditional Chinese medicine for neuroprotection.
• Immune and inflammatory systems: Inhibition of NF-κB and NLRP3 pathways observed in preclinical research.

Betaine is mainly distributed in the kidneys, liver, and brain.

6. Dosage Forms and Doses Used in Studies

Betaine anhydrous has most often been used by adults in doses of 1.25 to 3 grams by mouth twice daily. The following doses have been used in specific published studies:

• Homocystinuria (FDA-approved prescription use): Only doses of betaine >6 g/d lower plasma homocysteine in hyperhomocysteinemic patients with genetic defects in homocysteine metabolism.
• Homocysteine lowering in healthy adults (meta-analysis): Supplementation of betaine at 4 to 6 g/d significantly lowers plasma homocysteine concentration in healthy adults by 1.23 μmol/L or 11.8% of baseline values.
• Lipid effects (randomized trials, Olthof et al.): Participants ingested 1.5 g/d of betaine (study 2, n=19), 3 g/d of betaine (study 2, n=18), or 6 g/d of betaine (studies 1 and 2 combined, n=31) over 2 to 6 weeks.
• NASH randomized controlled trial (Abdelmalek et al., 2009): Patients received oral betaine (20 g daily) or placebo for 12 months.
• NAFLD interventional study: Trimethylglycine was administered as 2 sachets three times daily for 1 month, followed by 1 sachet three times daily for 2 months, each sachet containing 3 g betaine.
• Athletic performance (short-term, standard protocol): The standard supplemental protocol involved 1.25 g of trimethylglycine, usually in 250 mL of carbohydrate solution, taken twice daily for two weeks.
• Athletic performance (handball players, crossover): Betaine was given at 2.5 g/d for 14 days in a double-blind crossover study design.
• Collegiate athletes (6-week study): Sixteen male collegiate athletes received 5 g/day of betaine for 6 weeks.
• Alcoholic fatty liver: For people with alcohol-induced fatty liver, the recommended amount for betaine citrate or betaine aspartate supplementation is 1,000 to 2,000 mg three times daily.

Regarding upper limits, many authors suggest that the maximum daily intake of betaine is 9–15 g, with 20 g being the maximum.

7. Safety Considerations and Interactions

General Safety Status

In the United States, betaine is generally recognized as a safe (GRAS) ingredient, while in Europe it has approval for use in food from the European Commission (EC). Betaine is a stable and nontoxic natural substance. Betaine is not an essential nutrient, and thus no deficiency state exists.

LDL Cholesterol and Lipid Elevations

One of the most clinically significant documented concerns from human trials is an effect on blood lipids. Betaine supplementation (6 g/d) for 6 weeks increased blood LDL cholesterol concentrations by 0.36 mmol/L and triacylglycerol concentrations by 0.14 mmol/L relative to placebo. The ratio of total to HDL cholesterol increased by 0.23. Concentrations of HDL cholesterol were not affected. Doses of betaine lower than 6 g/d also raised LDL cholesterol, but these changes were not statistically significant. Furthermore, the effect of betaine on LDL cholesterol was already evident after 2 weeks of intervention.

A 2019 systematic review and meta-analysis assessed this across six randomized controlled trials. Six randomized controlled trials published between 2002 and 2018 were identified. All six studies used adult participants supplemented with at least 4 g/d of betaine for six to twenty-four weeks. The pooled estimate of the effects of betaine supplementation compared to placebo on total cholesterol was 0.34 mmol/L (95% CI: 0.02, 0.65), p=0.0352. No significant effect was observed for LDL, HDL, or TG individually. Supplementation with at least 4 g/d of betaine for a minimum of six weeks may moderately increase plasma total cholesterol, which might be important in the context of cardiovascular health.

This finding is notable because while some studies suggest TMG may lower homocysteine levels and thus reduce heart disease risk, the evidence is mixed, and concerns have been raised about its effect on cholesterol levels, which might negate any cardiovascular benefits.

Hypermethioninemia

The most common side effect in medical applications is elevated blood methionine levels. In rare cases, TMG could also significantly increase the amount of methionine in the blood, which could cause fluid buildup around the brain. This risk is most prominent in the context of high-dose prescription use for homocystinuria, where prescription betaine is used medically but can cause very high methionine and rare cerebral edema — this requires physician supervision, per the FDA label.

Gastrointestinal Effects

Nausea, diarrhea, bloating, and stomach discomfort can occur, especially at larger doses (also seen with prescription betaine), per the FDA Cystadane label.

Interactions with Other Supplements and Medications

Betaine functions very closely with choline, folic acid, vitamin B12, and SAMe — all of which function as methyl donors — meaning that supplementation with betaine can affect the overall methylation status and interact with these co-factors. Because betaine and SAMe share overlapping methylation pathways, co-administration may amplify methylation beyond intended levels. Additionally, the marketing of betaine hydrochloride as a digestive aid was banned in the United States due to insufficient evidence to classify it as "generally recognized as safe and effective" for that specified use, underscoring the importance of distinguishing different betaine salts and their intended applications.

Pregnancy and Pediatric Populations

There is not enough reliable information to know if betaine anhydrous is safe to use when pregnant or breastfeeding. Betaine anhydrous is likely safe for most children when taken by mouth in doses up to 150 mg/kg daily based on evidence from its use in pediatric homocystinuria patients; however, use in healthy children has not been systematically studied.

Excretion and Metabolic Handling

Even at high doses of 100 mg per kg of human weight, betaine is mostly used up through metabolic pathways and not excretion. However, betaine can be present in the urine of individuals with kidney disorders and diabetes. Subacute studies in rats have shown that betaine is not toxic when added at 0–5% of the total diet.

References

• Yamaguchi et al. — High loading of trimethylglycine promotes aqueous solubility of poorly water-soluble cisplatin. PubMed (2021)
• Filipčev et al. — Betaine as a Functional Ingredient: Metabolism, Health-Promoting Attributes, Food Sources, Applications and Analysis Methods. PMC / Molecules (2023)
• EBSCO Research Starters — Trimethylglycine as a Therapeutic Supplement. Consumer Health
• ScienceDirect Topics — Trimethylglycine (Pharmacology/Toxicology overview)
• Wikipedia — Trimethylglycine
• Wikipedia — Betaine
• Zhao et al. — Betaine in Inflammation: Mechanistic Aspects and Applications. Frontiers in Immunology / PMC (2018)
• ScienceDirect Topics — Trimethylglycine (Neuroscience overview)
• Examine.com — Betaine (Trimethylglycine): Benefits, Dosage, and Side Effects
• PeaceHealth Health Information Library — Betaine (Trimethylglycine)
• Olthof et al. — Effect of Homocysteine-Lowering Nutrients on Blood Lipids: Results from Four Randomised, Placebo-Controlled Studies in Healthy Humans. PLOS Medicine (2005)
• Olthof et al. — Effect of homocysteine-lowering nutrients on blood lipids. PubMed (2005)
• Olthof & Verhoef — Low Dose Betaine Supplementation Leads to Immediate and Long Term Lowering of Plasma Homocysteine. Journal of Nutrition (2003)
• Gao et al. — Betaine Supplementation Moderately Increases Total Cholesterol Levels: A Systematic Review and Meta-Analysis. PubMed (2019)
• Olthof et al. — Acute Effect of Folic Acid, Betaine, and Serine Supplements on Flow-Mediated Dilation after Methionine Loading: A Randomized Trial. PMC (2006)
• Bjelland et al. — Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysis. PMC (2013)
• Abdelmalek et al. — Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. PubMed / Hepatology (2009)
• Abdelmalek et al. — Betaine for nonalcoholic fatty liver disease. Hepatology / Wiley (2009)
• Larter et al. — Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance. PMC (2010)
• Nobari et al. — Effects of short-term betaine supplementation on muscle endurance and indices of endocrine function following acute high-intensity resistance exercise in young athletes. PMC (2022)
• Chen et al. — Effects of 6-Week Betaine Supplementation on Muscular Performance in Male Collegiate Athletes. PMC (2022)
• Tomaszek et al. — Betaine (TMG) as a Dietary Supplement in Sports: Mechanisms of Action, Ergogenic Effects, and Safety of Use. Quality in Sport (2025)
• Examine.com — Research Breakdown on Betaine
• Warskulat et al. — Betaine Transport in Kidney and Liver: Use of Betaine in Liver Injury. Cellular Physiology and Biochemistry / Karger (2013)
• Bröer & Bröer — The betaine/GABA transporter and betaine: roles in brain, kidney, and liver. Frontiers in Physiology (2014)
• Slama et al. — Hypertensive rats show increased renal excretion and decreased tissue concentrations of glycine betaine. PMC (2024)
• USDA ARS — Betaine Concentration of Common Foods in the US (2004)
• Encyclopedia MDPI — Betaine as a Functional Ingredient
• WebMD — Betaine Anhydrous: Overview, Uses, Side Effects, Dosing
• Naderi et al. — Effects of betaine supplementation on endurance exercise performance: a systematic review. PMC (2025)